Improving the efficacy of RAAS blockade in patients with chronic kidney disease.
about
Social Determinants of Racial Disparities in CKD.Obesity in kidney disease: A heavyweight opponent.Safety of ACE inhibitor therapies in patients with chronic kidney disease.Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.Extracellular Superoxide Dismutase Protects against Proteinuric Kidney DiseaseWnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease.The effect of RAAS blockade on the progression of diabetic nephropathy.Integrated Assessment of Pharmacological and Nutritional Cardiovascular Risk Management: Blood Pressure Control in the DIAbetes and LifEstyle Cohort Twente (DIALECT).Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology.Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.Renal endothelial function is associated with the anti-proteinuric effect of ACE inhibition in 5/6 nephrectomized rats.Keap1 hypomorphism protects against ischemic and obstructive kidney diseaseA practical approach to dietary interventions for nondialysis-dependent CKD patients: the experience of a reference nephrology center in BrazilRenin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.Personalized evaluation based on quantitative proteomics for drug-treated patients with chronic kidney disease.High sodium intake is associated with important risk factors in a large cohort of chronic kidney disease patients.Sodium restriction potentiates the renoprotective effects of combined vitamin D receptor activation and angiotensin-converting enzyme inhibition in established proteinuric nephropathy.Pathological presentation of cardiac mitochondria in a rat model for chronic kidney disease.
P2860
Q30250319-8A71F2F4-D691-487D-A55A-179EF6909EF8Q34367664-D2D7DE8A-2CC0-47DC-928C-53C8A0DAF784Q34434606-66FE7CD9-8790-4C74-8075-1BE4588502C3Q35086461-6DEA3E05-8168-4A08-82DC-BC47F1EA47F2Q36104801-BE34AC31-4418-4826-8D55-469745B7584EQ36908181-3E290ABA-CBED-4EB4-95C3-2CE5015717BEQ38168046-FB08FD2A-47AC-4C99-8792-A575206BE3CFQ38690284-E30D67C2-9722-4157-9CC4-7B0544B641DDQ38939078-F3488863-B0CF-4F69-BB69-2D6C2BD76ED4Q39112475-FDF25D97-4527-4620-A90E-D3A2210EE361Q39971417-9ACC877B-453C-4730-BF23-18B5805E7AA2Q41645053-247793C2-211F-48BE-83C8-814AB3961E3AQ42416678-E7456DF4-6E72-444F-9CDD-A95CAAF3B6F5Q44543266-2C60ACED-6F2D-4F9C-AEDB-8B245CFC4D12Q47324570-B079B757-2A58-4971-8B50-3CFFFB23234EQ51027996-AB3A9679-FDEA-4148-A1A6-F3FFC2A0D754Q53676046-1C1EDE40-79AD-4FED-AD0D-7EC84C652D71Q55317832-D56DF7B7-1CCF-402E-A34B-3E5551BB2210
P2860
Improving the efficacy of RAAS blockade in patients with chronic kidney disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Improving the efficacy of RAAS blockade in patients with chronic kidney disease.
@en
type
label
Improving the efficacy of RAAS blockade in patients with chronic kidney disease.
@en
prefLabel
Improving the efficacy of RAAS blockade in patients with chronic kidney disease.
@en
P2093
P2860
P356
P1476
Improving the efficacy of RAAS blockade in patients with chronic kidney disease.
@en
P2093
Gerjan J Navis
Hiddo J Lambers Heerspink
Martin H de Borst
Stephan J L Bakker
P2860
P2888
P304
P356
10.1038/NRNEPH.2012.281
P407
P577
2012-12-18T00:00:00Z